TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1977781
Drug: Astemizole, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole, 10 mg
Study: 11246381
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac
Study: 15243302
Drug: Intravenous treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous treprostinil sodium
Study: 1386977
Drug: Ondansetron injection
Normalized name: ondansetron Injection
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron injection (4 mg once daily by intravenous administration for 3-5 consecutive days)
Study: 1386977
Drug: Ondansetron injection
Normalized name: ondansetron Injection
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron injection
Study: 28267236
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day vonoprazan for 8 weeks
Study: 24053577
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture treatment two times per week for 4 weeks
Study: 12943178
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture treatment
Study: 16950986
Drug: Neonatal indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neonatal indomethacin treatment
Study: 11748505
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aerobic and strength training (P4 and P6)
Study: 7995681
Drug: GGGS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GGGS treatment
Study: 28961020
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 250 µg
Study: 2788406
Drug: Ostoprin (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ostoprin (4.0 g per day)
Study: 30666100
Drug: IND/GLY 110/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/GLY 110/50 µg once daily
Study: 28154349
Drug: 2.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/d of ALA‐DAG
Study: 21814588
Drug: Thiabendazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiabendazole (two daily doses of 25 mg/kg for two days)
Study: 15303645
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment intensity
Study: 10641044
Drug: Taiga Wurzel
Normalized name: Saiga tatarica horn extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taiga Wurzel (25 drops three times daily for 30 days)
Study: 10641044
Drug: Echinacea (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea (40 drops three times daily for 30 days)
Study: 30639581
Drug: BoNT‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injection
Study: 29846607
Drug: Once-daily modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily modified-release hydrocortisone
Study: 29846607
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily glucocorticoid doses
Study: 8865530
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH, continuous intravenous infusion)
Study: 2423343
Drug: Verapamil 3
Normalized name: verapamil 300 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 3 X 80 mg
Study: 19055813
Drug: FACT (Flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: FACT (Flexible Assertive Community Treatment)
Study: 8617708
Drug: Sertraline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (200 mg/day for 10 days)
Study: 2729124
Drug: Dilevalol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 200 mg
Study: 23643716
Drug: Usual physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual physiotherapy (1-to-1 advice, manual therapy, and exercise)
Study: 20336348
Drug: Cilengitide 500
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 500 mg IV twice weekly
Study: 19246849
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg and HCTZ 12.5 mg once daily
Study: 19246849
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg and HCTZ 12.5 mg once daily
Study: 9497019
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg nicotine patch (Nicotrol)
Study: 9497019
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg oral cotinine fumarate
Study: 9497019
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nicotine patch and cotinine
Study: 7979282
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g administered immediately before PE (group I)
Study: 7979282
Drug: Ceftriaxone 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 3 g administered immediately before PE (group I)
Study: 7979282
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g administered 6 hours before PE (group II)
Study: 1174085
Drug: Bumetanide 0.25
Normalized name: bumetanide 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 0.25 mg
Study: 27615542
Drug: Nutrition counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition counseling intervention (monthly one-on-one sessions for 12 months)
Study: 24810891
Drug: Endoluminal venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoluminal venous laser therapy (980 nm, continuous mode, 30 W)
Study: 3361417
Drug: Non-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment control
Study: 15537171
Drug: 1000mg paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg paracetamol (PCM) tablets alone (control)
Study: 11501511
Drug: Calcitriol 3
Normalized name: CALCITRIOL 3MCG/GM OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 3 microg g(‐1) ointment (Silkis ointment)
Study: 8778950
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg bid)
Study: 24685559
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy and motivational enhancement therapy with additional check-ups
Study: 24685559
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy and motivational enhancement therapy without additional check-ups
Study: 23797469
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg CEE with or without 2.5 mg medroxyprogesterone acetate
Study: 22350925
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin (PR-M) 2 mg
Study: 16809807
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin daily for 2 months
Study: 16809807
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg simvastatin daily for 2 months
Study: 8980590
Drug: Ivermectin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (up to 10 doses at 6-month intervals)
Study: 18458219
Drug: Candesartan (8-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8-16 mg once daily)
Study: 16451284
Drug: Short-burst oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-burst oxygen therapy
Study: 31796225
Drug: A/Slovenia vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/Slovenia vaccine strain
Study: 28628269
Drug: Methylphenidate extended-release
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate extended-release oral suspension (MEROS) 60 mg under fed conditions
Study: 28628269
Drug: Methylphenidate extended-release
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate extended-release oral suspension (MEROS) 60 mg under fasting conditions
Study: 16760316
Drug: MCV (Meningococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV (Meningococcal group C polysaccharide-protein conjugate vaccine)
Study: 24432673
Drug: Simulated agent
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated agent granules
Study: 9108848
Drug: Diphtheria-tetanus-pertussis toxoids
Normalized name: DIPHTHERIA/TETANUS/PERTUSSIS VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus-pertussis toxoids vaccine
Study: 9108848
Drug: Diphtheria-tetanus toxoids
Normalized name: diphtheria-tetanus toxoids (DT) ped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus toxoids vaccine
Study: 6201083
Drug: Dextran infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran infusion
Study: 25917860
Drug: Subacromial corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial corticosteroid injection
Study: 14714107
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg every 12 h for 7-21 days
Study: 14714107
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g every 12 h for 7-21 days
Study: 8243022
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/day for 3 weeks, followed by 10 mg/day for 9 weeks
Study: 350144
Drug: Tetracycline hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline hydrochloride capsules
Study: 28290057
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum supplementation (Col), 20 g/day for 14 days
Study: 23651846
Drug: Nutrient infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nutrient infusion into mid-jejunum
Study: 21865355
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (AMIO-ON group)
Study: 21865355
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (AMIO-OFF group)
Study: 17160982
Drug: Central body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central body fat distribution and centralized subcutaneous fat (factors 1 and 2)
Study: 15067098
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (ciprofloxacin 200 mg and amoxicillin-clavulanate 375 mg every 8 h)
Study: 11444419
Drug: Lutein (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (15 mg)
Study: 11444419
Drug: Lycopene (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (15 mg)
Study: 11367649
Drug: Tongmai Jiangzhi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongmai Jiangzhi Oral Liquid (TJOL)
Study: 3248127
Drug: Dialysate with
Normalized name: Dialyvite 800 with Zinc Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate with high calcium concentration (1.68 +/- 0.07 mmol/L)
Study: 29438463
Drug: DHP107 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHP107 (200 mg/m2 orally twice daily days 1, 8, 15 every 4 weeks)
Study: 29438463
Drug: i.v. paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. paclitaxel (175 mg/m2 day 1 every 3 weeks)
Study: 7964484
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell lines from treatment-responsive Lyme arthritis
Study: 26659583
Drug: HU alone
Normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU alone (HU 500 mg BID)
Study: 23398960
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral interferon alpha
Study: 16848808
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection (30 IU Botox)
Study: 16848808
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of botulinum toxin and nitroglycerin
Study: 10951830
Drug: Verapamil COER-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil COER-24 180/240 mg (single daily dose at bedtime)
Study: 8981340
Drug: New matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: New matrix patch for estradiol delivery (active patch)
Study: 31580316
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (control)
Study: 27578562
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol
Study: 17976224
Drug: Intravenous nitroglycerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerine
Study: 31745072
Drug: High-dose eicosapentaenoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose eicosapentaenoic acid (EPA, 1.2g)
Study: 24621587
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care and a silicone‐adhesive patch (attention control) (n = 16)
Study: 8847044
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) therapy alone
Study: 8847044
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) therapy with G-CSF
Study: 6896965
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of morphine 2 mg
Study: 6896965
Drug: Intrathecal application
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal application of morphine
Study: 31829095
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous bone marrow mesenchymal stem cells (MSCINJ) with intensive atorvastatin (80 mg/d)
Study: 30175557
Drug: High CHO
Normalized name: High choriolytic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CHO (HCHO: 415 g) during recovery and moderate-intensity exercise (120SS)
Study: 20662675
Drug: Local infiltrations
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltrations of 1 mL articaine HCl 4% with epinephrine 1/200,000 to the ipsilateral mylohyoid and buccal nerves
Study: 20662675
Drug: Inferior alveolar
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inferior alveolar and buccal nerve blocks
Study: 19427768
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (mean HbA1c reduction of 0.9%)
Study: 2678309
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg + hydrochlorothiazide 15 mg/die
Study: 2678309
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg/die
Study: 18163165
Drug: MTX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX plus FA (20 mg/week)
Study: 1195163
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment options
Study: 25605698
Drug: DEX-IV (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX-IV (intravenous injection of dexamethasone 0.5 mg/kg, maximum dose 24 mg)
Study: 17077809
Drug: Olanzapine 2.5
Normalized name: olanzapine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 2.5 mg/day
Study: 9169300
Drug: Olanzapine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (all doses)
Study: 11719736
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily for 8 days
Study: 11719736
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg 4 times daily on day 8
Study: 27346078
Drug: Corn starch
Normalized name: Corn Starch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn starch fiber at 90 g/day (multiple-serving study)
Study: 27346078
Drug: Corn starch
Normalized name: Corn Starch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn starch fiber at 50 g/day (single-dose study)
Study: 27346078
Drug: Corn starch
Normalized name: Corn Starch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn starch fiber at 60 g (multiple servings)
Study: 22871048
Drug: Polyherbal Unani
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyherbal Unani formulation (topical application)
Study: 22871048
Drug: Sodium thiosulphate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulphate lotion (20%) (control group)
Study: 17091134
Drug: Oral-B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B CrossAction (CA) toothbrush
Study: 11567957
Drug: Latanoprost 50
Normalized name: Latanoprost 50 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 50 microg/ml applied four times daily
Study: 11567957
Drug: Latanoprost 50
Normalized name: Latanoprost 50 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 50 microg/ml applied once daily
Study: 11567957
Drug: Latanoprost 50
Normalized name: Latanoprost 50 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 50 microg/ml applied once daily after 3 weeks without treatment
Study: 8501156
Drug: Loxiglumide (CCK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (CCK receptor antagonist)
Study: 21978235
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac 0.5% drops for 3 months (group 1)
Study: 15632770
Drug: CR2 (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR2 (weekly supervised sessions for 26 weeks followed by one supervised session per month for the remaining 26 weeks)
Study: 11719356
Drug: Intravenous Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Cyclosporine A (CsA)
Study: 27601379
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment effect
Study: 28976412
Drug: Epitiram (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epitiram (generic drug)
Study: 21815864
Drug: Telaprevir (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telaprevir (3 × 750 mg/day) alone
Study: 11217910
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (SALM/FP) via Diskus inhaler 50/100 microg, twice daily
Study: 11217910
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 microg via chlorofluorocarbon MDI, twice daily
Study: 8019763
Drug: Intravenous lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lithium (4 mEq kg‐1) in diabetic rats
Study: 8019763
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (0.5 g kg‐1) in both groups
Study: 8019763
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment in both normal and diabetic rats
Study: 30804032
Drug: Surgeons receiving
Normalized name: sturgeon, unspecified preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgeons receiving a report detailing patients' goals and treatment preferences
Study: 30804032
Drug: Surgeons not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgeons not receiving a report detailing patients' goals and treatment preferences
Study: 23745526
Drug: Arformoterol aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arformoterol aerosol solution (15μg/2mL) via nebulizer
Study: 11393591
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/day)
Study: 12430728
Drug: Moisturizer applied
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizer applied once daily for 3 weeks
Study: 12430728
Drug: Moisturizer applied
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizer applied twice daily for 3 weeks
Study: 9820354
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg oral ciprofloxacin
Study: 31483964
Drug: Mitapivat 50
Normalized name: mitapivat 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitapivat 50 mg twice daily
Study: 31483964
Drug: Mitapivat 300
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitapivat 300 mg twice daily
Study: 12048127
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg/day
Study: 7926408
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of ivermectine (200 mcg/Kg)
Study: 3096764
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (1.5 mg/Kg/day) for 18 days